| Routes of|
|Part of a series on the|
GX-19 is a COVID-19 vaccine candidate developed by Genexine consortium.
It is a DNA-based vaccine that encodes the SARS-CoV-2 spike protein.
A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 (COVID‑19). Prior to the COVID‑19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). This knowledge accelerated the development of various vaccine platforms during early 2020. The initial focus of SARS-CoV-2 vaccines was on preventing symptomatic, often severe illness. On 10 January 2020, the SARS-CoV-2 genetic sequence data was shared through GISAID, and by 19 March, the global pharmaceutical industry announced a major commitment to address COVID-19. The COVID‑19 vaccines are widely credited for their role in reducing the spread, severity, and death caused by COVID-19.
Valneva COVID-19 vaccine, also known as the VLA2001 and VLA2101 , is a COVID-19 vaccine candidate developed by French biotechnology company Valneva SE in collaboration with American company Dynavax Technologies.
The CureVac COVID-19 vaccine was a COVID-19 vaccine candidate developed by CureVac N.V. and the Coalition for Epidemic Preparedness Innovations (CEPI). The vaccine showed inadequate results in its Phase III trials with only 47% efficacy.
ZyCoV-D is a DNA plasmid-based COVID-19 vaccine developed by Indian pharmaceutical company Cadila Healthcare, with support from the Biotechnology Industry Research Assistance Council. It is approved for emergency use in India.
SCB-2019 is a protein subunit COVID-19 vaccine developed by Clover Biopharmaceuticals using an adjuvant from Dynavax technologies. Positive results of Phase I trials for the vaccine were published in The Lancet and the vaccine completed enrollment of 29,000 participants in Phase II/III trials in July 2021. In September 2021, SCB-2019 announced Phase III results showing 67% efficacy against all cases of COVID-19 and 79% efficacy against all cases of the Delta variant. Additionally, the vaccine was 84% effective against moderate cases and 100% effective against hospitalization.
The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV, is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Peer-reviewed results show WIBP-CorV 72.8% effective against symptomatic cases and 100% against severe cases. The other inactivated virus COVID-19 vaccine developed by Sinopharm is BBIBP-CorV which is comparably more successful. 1 billion doses are expected to be produced per year.
The MVC COVID-19 vaccine, designated MVC-COV1901 and also known as the Medigen COVID-19 vaccine , is a protein subunit COVID-19 vaccine developed by Medigen Vaccine Biologics Corporation in Taiwan, American company Dynavax Technologies and the U.S. National Institute of Health.
UB-612 is a COVID-19 vaccine candidate developed by United Biomedical, Inc. Asia, Vaxxinity, and DASA. It is a peptide vaccine.
A viral vector vaccine is a vaccine that uses a viral vector to deliver genetic material coding for a desired antigen into the recipient's host cells. As of April 2021, six viral vector vaccines have been authorized for use in humans in at least one country: four COVID-19 vaccines and two Ebola vaccines.
Minhai COVID-19 vaccine, trademarked as KCONVAC, is a COVID-19 vaccine developed by Shenzhen Kangtai Biological Products Co. Ltd and its subsidiary, Beijing Minhai Biotechnology Co., Ltd.
NDV-HXP-S is a COVID-19 vaccine candidate developed by a team led by Jason McLellan at the University of Texas at Austin, together with groups from the Icahn School of Medicine at Mount Sinai and the National Institute of Allergy and Infectious Diseases Vaccine Research Center, based on an improved spike protein central to its resilience and efficacy.
EuCorVac-19 is a COVID-19 vaccine candidate developed by EuBiologics Co.
Razi Cov Pars is a COVID-19 vaccine candidate developed by the Iranian Razi Vaccine and Serum Research Institute.
COVID-19 vaccination in Japan started later than in most other major economies. The country has frequently been regarded "slow" for its vaccination efforts.
COVI-VAC is a COVID-19 vaccine being developed by Codagenix, Inc. It is currently in Phase I clinical trials, involving 48 participants which runs from December 2020 to June 2021.
FAKHRAVAC is a COVID-19 vaccine developed in Iran by the Organization of Defensive Innovation and Research, a subsidiary of Iran's Ministry of Defense. It's the third Iranian COVID-19 vaccine reaching clinical trials. It's currently in phase III. It has received emergency use authorization in Iran on 9 September 2021.
COVAX-19 is a recombinant protein-based COVID-19 vaccine developed by South Australian based biotech company Vaxine. It is under clinical trial in collaboration with the Iranian company CinnaGen.
GBP510 is a COVID-19 vaccine candidate developed by SK Bioscience and GSK.
AdCLD-CoV19 is a COVID-19 vaccine candidate developed by Cellid Co, a company from South Korea.
COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness and safety. 24 vaccines are authorized for use by national governments, including six approved for emergency or full use by at least one WHO-recognised stringent regulatory authority; while five are in Phase IV. 204 vaccines are undergoing clinical trials that have yet to be authorized. Nine clinical trials consider heterologous vaccination courses.
|Scholia has a profile for GX-19 (Q106616276).|